Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03038230 · ClinicalTrials.gov registry record · Phase 1

MCLA-117 in Acute Myelogenous Leukemia

A Phase 1 study, sponsored by Merus B.V..

Terminated
Registry status
Phase 1
Development phase
80
Enrollment target

NCT03038230: Clinical Trial Phase 1 study, sponsored by Merus B.V..

NCT03038230 is a Phase 1 study that was terminated before completion, run by Merus B.V.. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03038230, a Phase 1 study, was terminated before completion, sponsored by Merus B.V..

TERMINATED
Registry status
Phase 1
Development phase
80 participants
Enrollment target

Study Summary

This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.

Primary Outcome

Evaluation of number of participants with treatment related toxicity observed during a dose escalation step for 1 Cycle

Interventions

  • DRUG MCLA-117 bispecific antibody

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2016-04
Est. Completion 2021-05-11
Phase Phase 1
Merus B.V.

8 total trials

Why NCT03038230 stopped before completion

NCT03038230 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).

The record links to 0 conditions, and to 1 intervention - of which MCLA-117 bispecific antibody is the first listed.

NCT03038230 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03038230 about?

NCT03038230 is a clinical study titled "MCLA-117 in Acute Myelogenous Leukemia". This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.

What is the current status of trial NCT03038230?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2016-04. Estimated completion is 2021-05-11.

What interventions are being tested in trial NCT03038230?

The interventions under investigation include: MCLA-117 bispecific antibody (DRUG).

Who is sponsoring clinical trial NCT03038230?

This trial is sponsored by Merus B.V., which has 8 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03038230's enrollment target sits among peer trials

80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT03038230, the US trial registry maintained by the National Library of Medicine. NCT03038230 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.